Cancer Diagnosis: Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
Medication: ELZONRIS™ (tagraxofusp-erzs)

This medication may be associated with serious side effects, including Capillary Leak Syndrome (CLS). Symptoms of CLS include changes in serum albumin, rapid weight gain, edema, fluid retention, and hypotension.

Boxed WARNING: CAPILLARY LEAK SYNDROME
• Capillary Leak Syndrome (CLS), which may be life-threatening or fatal, can occur in patients receiving ELZONRIS. Monitor for signs and symptoms of CLS and take actions as recommended.

Please see full Prescribing Information, including Boxed WARNING, at ELZONRIS.com/hcp.
Patient Name: ____________________________________________

ELZONRIS Start Date: ______________________________________

Prescribing Physician: ______________________________________

Physician Phone Number: ____________________________________

Contact the patient’s physician immediately for further information.

Copyright 2019 - Stemline Therapeutics, Inc.  All rights reserved.  3/2019  US-ELZ-1900027